BRPI0820481A2 - Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina - Google Patents

Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina

Info

Publication number
BRPI0820481A2
BRPI0820481A2 BRPI0820481-0A BRPI0820481A BRPI0820481A2 BR PI0820481 A2 BRPI0820481 A2 BR PI0820481A2 BR PI0820481 A BRPI0820481 A BR PI0820481A BR PI0820481 A2 BRPI0820481 A2 BR PI0820481A2
Authority
BR
Brazil
Prior art keywords
heterocycloalkyloxy
cycloalkyloxy
histamine
receptor modulators
pyridine compounds
Prior art date
Application number
BRPI0820481-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael A Letavic
Emily M Stocking
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40297867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0820481(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0820481A2 publication Critical patent/BRPI0820481A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0820481-0A 2007-11-20 2008-11-17 Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina BRPI0820481A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98924607P 2007-11-20 2007-11-20
PCT/US2008/083764 WO2009067401A1 (en) 2007-11-20 2008-11-17 Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor

Publications (1)

Publication Number Publication Date
BRPI0820481A2 true BRPI0820481A2 (pt) 2015-06-16

Family

ID=40297867

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820481-0A BRPI0820481A2 (pt) 2007-11-20 2008-11-17 Composotos cicloalquilóxi e heterocicloalquilóxi piridina como moduladores do receptor de h3 de histamina

Country Status (22)

Country Link
US (1) US8883776B2 (enExample)
EP (1) EP2222664B1 (enExample)
JP (1) JP5498390B2 (enExample)
KR (1) KR101546712B1 (enExample)
CN (2) CN101868454A (enExample)
AR (2) AR069387A1 (enExample)
AU (1) AU2008326561B2 (enExample)
BR (1) BRPI0820481A2 (enExample)
CA (1) CA2706328C (enExample)
CL (1) CL2008003465A1 (enExample)
CO (1) CO6210700A2 (enExample)
CR (1) CR11529A (enExample)
EA (1) EA018582B1 (enExample)
EC (1) ECSP10010190A (enExample)
MX (1) MX2010005488A (enExample)
MY (1) MY158253A (enExample)
NI (1) NI201000086A (enExample)
NZ (1) NZ584998A (enExample)
TW (1) TWI491604B (enExample)
UA (1) UA103468C2 (enExample)
WO (1) WO2009067401A1 (enExample)
ZA (1) ZA201004334B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8288389B2 (en) * 2007-09-06 2012-10-16 Glaxo Group Limited Piperazine derivative having affinity for the histamine H3 receptor
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
CA2721303C (en) * 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
DK2429996T3 (en) 2009-03-18 2017-06-19 Janssen Pharmaceutica Nv Process for the preparation of histamine h3 receptor modulators
RU2012116124A (ru) * 2009-09-21 2013-10-27 Вандербилт Юниверсити О-БЕНЗИЛ НИКОТИНАМИДНЫЕ АНАЛОГИ КАК ПОЗИТИВНЫЕ АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ mGluR5
EP2729130B1 (en) 2011-07-07 2017-09-06 Janssen Sciences Ireland UC Darunavir combination formulations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE817911C (de) 1947-12-16 1951-10-22 Chem Fab Tempelhof Preuss & Te Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden
BE726551A (enExample) 1968-01-22 1969-06-16
ES436109A1 (es) 1974-04-04 1977-01-01 Christiaens Sa A Procedimiento para la preparacion de nuevos derivados de pi-ridina.
EP0089765A3 (en) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Pyridine derivatives
GB8311443D0 (en) 1983-04-27 1983-06-02 Smith Kline French Lab Chemical compounds
GB8320505D0 (en) 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
GB8332091D0 (en) 1983-12-01 1984-01-11 Smith Kline French Lab Chemical compounds
JPS61149119A (ja) 1984-12-22 1986-07-07 旭光学工業株式会社 検眼用試験枠
US4792547A (en) 1985-12-26 1988-12-20 Hokuriku Pharmaceutical Co., Ltd. Pyrazine-2-carboxamide derivatives useful in treating allergic disease
JPH0637595B2 (ja) 1986-08-06 1994-05-18 日本ペイント株式会社 陰極電着塗料組成物
GB9025828D0 (en) 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
JP3354271B2 (ja) 1993-02-25 2002-12-09 三共株式会社 ピリジルオキシアミド誘導体
EP0761654B1 (en) 1995-08-24 2003-06-18 Basf Aktiengesellschaft Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides
EP0881217A4 (en) 1995-12-28 2000-01-26 Kureha Chemical Ind Co Ltd METHOD FOR PRODUCING PYRIDINE CARBOXAMIDES AND THIOCARBOXAMIDES
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
WO2000076984A2 (en) 1999-05-21 2000-12-21 Biovitrum Ab Novel compounds, their use and preparation
US6399607B1 (en) 1999-07-02 2002-06-04 Research Foundation-State University Of New York Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP2002322163A (ja) 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd ピペラジン誘導体
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
DE60230266D1 (de) 2001-06-15 2009-01-22 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
ES2294190T3 (es) 2001-11-01 2008-04-01 Janssen Pharmaceutica N.V. Derivados de amida como inhibidores de la glucogeno sintasa quinasa 3-beta.
HUP0402106A3 (en) 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
EP1474401A2 (en) 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
GB0206219D0 (en) 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
EP1575495A4 (en) 2002-03-27 2009-12-02 Smithkline Beecham Corp COMPOUNDS AND METHODS
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004037800A1 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
EP1558595B1 (en) 2002-10-23 2009-11-25 Janssen Pharmaceutica N.V. Piperazinyl and diazapanyl benzamides and benzthioamides
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
AU2004257025B9 (en) 2003-06-27 2010-05-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
WO2005009976A1 (en) 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
WO2005023247A1 (en) 2003-09-03 2005-03-17 Smithkline Beecham Corporation Compounds and methods
GB0324159D0 (en) * 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US7423147B2 (en) 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
ATE490959T1 (de) 2004-03-31 2010-12-15 Janssen Pharmaceutica Nv Heterocyclische nichtimidazolverbindungen als modulatoren des histamin-h3-rezeptors
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
SI1948607T1 (sl) 2005-09-16 2010-07-30 Janssen Pharmaceutica Nv Ciklopropil amini kot modulatorji histaminskega H3 receptorja
US7638531B2 (en) 2005-12-21 2009-12-29 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
US7879880B2 (en) 2005-12-21 2011-02-01 Schering Corporation Substituted aniline derivatives useful as histamine H3 antagonists
EP1994022A2 (en) 2006-03-15 2008-11-26 Wyeth a Corporation of the State of Delaware N-substituted-azacyclylamines as histamine-3 antagonists
WO2007143422A2 (en) 2006-05-30 2007-12-13 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2008002816A1 (en) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzamide modulators of the histamine h3 receptor
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
CO6210700A2 (es) 2010-10-20
NI201000086A (es) 2011-03-17
US8883776B2 (en) 2014-11-11
TW200936579A (en) 2009-09-01
HK1147994A1 (en) 2011-08-26
CA2706328C (en) 2016-04-19
MX2010005488A (es) 2010-06-01
ZA201004334B (en) 2011-10-26
JP2011503233A (ja) 2011-01-27
JP5498390B2 (ja) 2014-05-21
KR20100098636A (ko) 2010-09-08
EP2222664B1 (en) 2014-10-29
WO2009067401A1 (en) 2009-05-28
CL2008003465A1 (es) 2009-03-06
CA2706328A1 (en) 2009-05-28
EA201070637A1 (ru) 2010-12-30
AU2008326561B2 (en) 2013-12-05
UA103468C2 (ru) 2013-10-25
KR101546712B1 (ko) 2015-08-24
TWI491604B (zh) 2015-07-11
CN101868454A (zh) 2010-10-20
EA018582B1 (ru) 2013-09-30
ECSP10010190A (es) 2010-06-29
CN105712977A (zh) 2016-06-29
AR069387A1 (es) 2010-01-20
NZ584998A (en) 2012-08-31
CR11529A (es) 2012-10-25
AU2008326561A1 (en) 2009-05-28
CN105712977B (zh) 2021-06-29
MY158253A (en) 2016-09-30
EP2222664A1 (en) 2010-09-01
US20090131415A1 (en) 2009-05-21
AR110977A2 (es) 2019-05-22

Similar Documents

Publication Publication Date Title
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0910585A2 (pt) indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7
BRPI0815440A2 (pt) 5-substituidos 2- (alcoximetil) furanos
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0910679A2 (pt) 5-metil-1-(naftaleno-2-il)-1h-pirazóis úteis como inibidores de receptor sigma
BRPI0923305A2 (pt) moduladores de receptores toll-like
CR10930A (es) Moduladores receptores nicotinicos de acetilcolina
EP2362878A4 (en) APJ RECEPTOR COMPOUNDS
BRPI0909375A2 (pt) Moduladores de receptores de quimiocinas
BRPI0920648A2 (pt) Combinações pesticidas contendo sulfoxaflor
EP2260811A4 (en) DISPOSABLE DIAPERS
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
BRPI0907844A2 (pt) moduladores seletivos do receptor de andrógeno
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0913057A2 (pt) azetidinas e ciclobutanos como antagonistas de receptor de histamina h3
BRPI0910365A2 (pt) dispositivo de comunicação
CR10544A (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina
CU23870B1 (es) Derivados de ciclopropilamida como moduladores h3
BRPI0918064A2 (pt) distribuidor de substância
BRPI0915991A2 (pt) derivados de sulfamida substituída
BRPI0816922A2 (pt) Moduladores tieno e furo-pirimidina do receptor de histamina h4
BRPI0913961A2 (pt) dispositivo de amortecimento
BRPI0822058A2 (pt) Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
DE602008003849D1 (de) Lenkungsdämpfer
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2697 DE 13/09/2022.